http://pharmalicensing.com/rss/ Latest market and business intelligence from the leading publishers worldwide. en-us http://pharmalicensing.com/rss/ http://pharmalicensing.com/images/pharmalicensing_logo.gif 144 CARLSBAD, Calif.-- November 10, 2009-- The University of Cambridge and Life Technologies Corporation (NASDAQ:LIFE), announced today the formation of a collaboration to advance translational research... http://pharmalicensing.com/redirs/news_rss//public/news/view/499618/0/3/university-of-cambridge-and-life-technologies-collaborate-on-landmark-high-throughput-sequencing-hub-in-united-kingdom http://pharmalicensing.com/redirs/news_rss//public/news/view/499618/0/3/university-of-cambridge-and-life-technologies-collaborate-on-landmark-high-throughput-sequencing-hub-in-united-kingdom San Diego, CA - November 1, 2009 and Osaka, Japan - November 2, 2009 - Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) announced today that they have... http://pharmalicensing.com/redirs/news_rss//public/news/view/498197/0/3/amylin-pharmaceuticals-and-takeda-enter-into-worldwide-agreement-to-co-develop-and-commercialize-compounds-for-obesity http://pharmalicensing.com/redirs/news_rss//public/news/view/498197/0/3/amylin-pharmaceuticals-and-takeda-enter-into-worldwide-agreement-to-co-develop-and-commercialize-compounds-for-obesity FRANKLIN, Mass., October 29, 2009 -- Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a diabetes management company developing the needle-free Symphony(TM) tCGM System as a non-invasive, wireless,... http://pharmalicensing.com/redirs/news_rss//public/news/view/498600/0/3/echo-therapeutics-announces-significant-advance-in-development-of-its-one-piece-needle-free-symphony-tcgm-biosensor http://pharmalicensing.com/redirs/news_rss//public/news/view/498600/0/3/echo-therapeutics-announces-significant-advance-in-development-of-its-one-piece-needle-free-symphony-tcgm-biosensor October 26, 2009 -- Norgine BV today announced that it has purchased cetilistat, a novel treatment for obesity from Alizyme Therapeutics Limited. Norgine has acquired global rights to the product,... http://pharmalicensing.com/redirs/news_rss//public/news/view/498215/0/3/norgine-acquires-cetilistat http://pharmalicensing.com/redirs/news_rss//public/news/view/498215/0/3/norgine-acquires-cetilistat Paris, France - October 21, 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Wellstat Therapeutics Corporation announced today a global licensing agreement on PN2034, a novel oral... http://pharmalicensing.com/redirs/news_rss//public/news/view/496693/0/3/sanofi-aventis-and-wellstat-therapeutics-enter-into-an-exclusive-worldwide-licensing-agreement-for-novel-oral-agent-to-treat-type-ii-diabetes http://pharmalicensing.com/redirs/news_rss//public/news/view/496693/0/3/sanofi-aventis-and-wellstat-therapeutics-enter-into-an-exclusive-worldwide-licensing-agreement-for-novel-oral-agent-to-treat-type-ii-diabetes MONTREAL, CANADA - October 21, 2009 - Tolerx, Inc., a biopharmaceutical company developing novel therapies intended to treat diabetes, other autoimmune diseases and cancer by specifically modulating... http://pharmalicensing.com/redirs/news_rss//public/news/view/496702/0/3/tolerx-presents-otelixizumab-phase-2-dose-optimization-data-at-the-idfs-20th-world-diabetes-congress http://pharmalicensing.com/redirs/news_rss//public/news/view/496702/0/3/tolerx-presents-otelixizumab-phase-2-dose-optimization-data-at-the-idfs-20th-world-diabetes-congress Massachusetts - 21 Oct 2009 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces plans to file a Biologics License Application (BLA) with the U.S. Food and... http://pharmalicensing.com/redirs/news_rss//public/news/view/496711/0/3/shire-targets-fourth-quarter-filing-of-bla-for-replagal http://pharmalicensing.com/redirs/news_rss//public/news/view/496711/0/3/shire-targets-fourth-quarter-filing-of-bla-for-replagal MONTREAL, Canada, September 14, 2009 - ConjuChem Biotechnologies (TSX:CJB) today announced financial results for the third quarter of fiscal 2009, ended July 31, 2009. "During our fiscal third... http://pharmalicensing.com/redirs/news_rss//public/news/view/496661/0/3/conjuchem-announces-fiscal-2009-third-quarter-financial-results http://pharmalicensing.com/redirs/news_rss//public/news/view/496661/0/3/conjuchem-announces-fiscal-2009-third-quarter-financial-results